GXO Logistics Inc vs Neurocrine Biosciences Inc — how do they compare? GXO Logistics Inc trades at $53.36 (market cap $6.02B), while Neurocrine Biosciences Inc trades at $170.91 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.9× GXO Logistics Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| GXO | NBIX | |
|---|---|---|
Market Cap | $6.02B | $17.30B |
Sector | Industrials | Health |
52-Week High | $65.59 | $180.55 |
52-Week Low | $45.52 | $123.10 |
Enterprise Value | $11.18B | $16.39B |
Signals from Pluang's Aura AI — not financial advice
GXO Logistics (GXO) trades at $53.69, up 8.09% in the last session, with a bullish technical signal and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, including Q1 2026, and reported Q1 2026 revenue growth of 10.8% year-over-year. Positive news includes new partnership renewals and an upcoming Investor Day, reinforcing its position as the world's largest pure-play contract logistics provider.
The outlook is positive, with a consensus price target of $66.60 implying significant upside. Investment opportunities stem from operational growth and strategic focus on high-margin sectors, but risks include competitive pressures from Amazon and reliance on the retail sector. Earnings on August 5, 2026, will be a key catalyst.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Trailing returns across standard periods
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →